Vaccine News and Research

Latest Vaccine News and Research

CNBG, Aeras reach final agreement to develop new TB vaccines

The global fight against the tuberculosis epidemic receives a boost today as Aeras and the China National Biotec Group (CNBG) announce that they have reached final agreement to jointly develop new tuberculosis (TB) vaccines.

10 Jan 2012

Blacklisted British doctor sues journal

A British doctor who lost his medical license in the U.K. in 2010 and who was accused in a journal last year of publishing bogus research filed a defamation suit this week in state District Court in Travis County.

9 Jan 2012

Merck selects Idera Pharmaceuticals' TLR agonists for evaluation, use as vaccine adjuvant candidates

Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.

9 Jan 2012

Enrollment complete in Diamyd Phase II study for type 1 diabetes

A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical's diabetes vaccine Diamyd. The study is thus fully recruited.

9 Jan 2012

Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine

Colby Pharmaceutical Company (CPC) today announced publication of new results showing that a single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced-immune responses, -dose sparing, and -cross-clade influenza virus protection.

9 Jan 2012

MPIIB, QIAGEN partner to develop latent TB diagnostic test

QIAGEN N.V. and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime.

From QIAGEN Manchester Limited 9 Jan 2012

Positive results from BioCryst's BCX4208 Phase 2b study on gout

BioCryst Pharmaceuticals, Inc. announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone.

8 Jan 2012

Bristol-Myers Squibb signs definitive agreement to acquire Inhibitex

Bristol-Myers Squibb Company and Inhibitex, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger.

8 Jan 2012

Anthrax defenses need to be strengthened say experts

It has been a decade since the anthrax attacks brought home the reality of bioterrorism and the nation has a stockpile of some basic tools to fight back against a few of the threats that worry defense experts the most.

8 Jan 2012

New Zealand life science and health IT companies to showcase their products in San Francisco

New Zealand is well known for its wines and stunning scenery, but the country is also a great source of innovation in the life sciences. A delegation of New Zealand life sciences companies who have reached key stages in their development are joining the throngs of international therapeutics, medical device and health IT companies in San Francisco, January 9 - 12 to showcase their products and capabilities to potential corporate partners and investors.

7 Jan 2012

Pennsylvania Department of Health to provide free influenza and Tdap vaccines

The Department of Health will offer free influenza and Tetanus, Diphtheria and Pertussis (Tdap) vaccines at the 2012 Pennsylvania Farm Show, Jan. 9-13, from 9 a.m. to 4 p.m. each day.

7 Jan 2012

New HIV vaccine candidates show promise in monkeys

"The quest for a vaccine against AIDS is gaining momentum, with research published Wednesday identifying promising new candidates that protected monkeys against a powerful strain of the virus and that soon could be tested in humans," the Wall Street Journal reports.

6 Jan 2012

Scripps professor receives pair of notable grants to study kinesin

Sathyanaryanan Puthanveettil, an assistant professor on the Florida campus of The Scripps Research Institute, has been awarded a pair of notable grants to study a critical component of long-term memory formation.

6 Jan 2012

Bringing health solutions to women, children

In this Huffington Post "Impact" blog post, Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, writes that she will be visiting Bangladesh to "learn even more about two of the biggest killers of children -- pneumonia and diarrhea," and says "Bangladesh has made incredible progress in recent years, reducing the number of childhood deaths by 65 percent since 1990."

6 Jan 2012

SonoPhoto Dynamic Therapy shows promise against squamous cell carcinoma

George Miller developed an ulcer on his bottom lip that began to bleed. His doctor sent cell scrapings to a pathologist, and diagnosed Miller with squamous cell carcinoma (SCC). According to TMD Limited, a medical tourism company, squamous cell carcinoma is the 2nd most common cancer in humans and other animals.

6 Jan 2012

Wake Forest Baptist participates in novel brain tumor vaccine clinical trial

A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

6 Jan 2012

Tetragenetics reports results from G-SOME H5N1 vaccine preclinical study

Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1 avian influenza strain.

6 Jan 2012

Researchers identify potential target for schistosomiasis vaccine

In the complicated life cycle of ancient flatworms that cause schistosomiasis, Case Western Reserve University researchers have identified a gene activator crucial to development of the parasites within humans - a potential target for a vaccine.

6 Jan 2012

Hepatitis C vaccine succeeds in an early phase clinical trial

An early phase clinical trial of a hepatitis C vaccine has shown promising results, according to researchers at Oxford University. The virus causing Hepatitis C is a difficult one since it changes its appearance, making creation of a vaccine against it a challenge.

5 Jan 2012

Midatech raises £6.3M through private investment round

Midatech Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, announced today it has raised £6.3 million through a private investment round.

5 Jan 2012